WALTHAM, Mass., Sept. 26, 2018 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced that
Briggs W. Morrison, M.D., Chief
Executive Officer of Syndax, will present at the 2018 Cantor Global
Healthcare Conference on Wednesday, October
3, 2018 at 9:10 a.m. ET at the
InterContinental New York Barclay Hotel.
A live webcast of the Company's presentation can be accessed
from the Investor section of the Company's website at
www.syndax.com, where a replay of the events will also be available
for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies. The
Company is developing its lead product candidate, entinostat, a
once-weekly, oral, small molecule, class I HDAC inhibitor, in
combination with exemestane and several approved PD-1/PD-L1
antagonists. The Company's pipeline also includes SNDX-6352, a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor, as well as a portfolio of potent and selective
inhibitors targeting the binding interaction of Menin with MLLr.
For more information, please visit www.syndax.com or follow the
Company on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-to-present-at-the-2018-cantor-global-healthcare-conference-300718999.html
SOURCE Syndax Pharmaceuticals, Inc.